Benzodiazepine UsePsycho-MGNCT07379073
Evaluation of a Clinical Support Website for the Management of Common Mental Health Conditions in Primary Care on Compliance With Benzodiazepine Prescribing Recommendations
A study testing Training in people with Benzodiazepine Use, run by MSPU de Pins-Justaret.
Trial summary
This cluster-randomized study aims to evaluate the impact of a web-based clinical support tool on adherence to recommended maximum durations for benzodiazepine prescriptions among new users in primary care. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Benzodiazepine Use
- What is being tested?
- Training
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- No sites listed yet
- Study dates
- 1 Jun 2026to 1 Oct 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Being a general practitioner or a specialist in general medicine.
- Practicing in the Occitanie region.
- Working in private practice.
- Being registered under Sector 1 fee agreements.
- Providing informed consent to participate in the study.
- Having computer equipment in the medical office, available during consultation (desktop, laptop, tablet, or smartphone) with internet access.
Who cannot join
- Physicians who have been practicing for less than two years, as they are unlikely to have sufficient retrospective data on prescription reimbursements for their patients.
About this study
This cluster-randomized study aims to evaluate the impact of a web-based clinical support tool on adherence to recommended maximum durations for benzodiazepine prescriptions among new users in primary care. General practitioners (GPs) participating in the study will have access to the website, which provides evidence-based algorithms for the management of common mental health conditions, including anxiety and sleep disorders. Prescription data and patient characteristics will be extracted from the French national health insurance database (DCIR). The primary outcome is the proportion of new benzodiazepine users whose prescriptions comply with recommended duration guidelines. Multilevel logistic regression models will assess the intervention effect, adjusting for patient- and GP-level factors.
- Conditions
- Benzodiazepine Use
- Being tested
- Training
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TrainingOther
Training intervention on benzodiazepine prescribing with access to the PsychoMG website providing evidence-based clinical decision algorithms for anxiety and sleep disorder management.
| Study group | Role | What they receive |
|---|---|---|
| Experimental Group (trained on PsychoMG website) | Experimental | Training intervention on benzodiazepine prescribing with access to the PsychoMG website providing evidence-based clinical decision algorithms for anxiety and sleep disorder management. Receives: Other: Training |
| Control Group | No intervention | Training intervention on benzodiazepine prescribing without access to the PsychoMG website providing evidence-based clinical decision algorithms for anxiety and sleep disorder management. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Compliance with recommended maximum duration of benzodiazepine prescriptions among new users
Primary outcome measure: adherence to recommended prescription duration (yes/no) for benzodiazepines
A patient is considered to have a prescription duration for benzodiazepines that is either adherent or non-adherent if they had no benzodiazepine exposure in the previous year and their duration of exposure during the first treatment episode:
- is less than 12 weeks for anxiolytic benzodiazepines,
- is less than 28 days for hypnotic benzodiazepines and related drugs, in accordance with current recommendations.
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Jan 2026
- Study start1 Jun 2026 (estimated)
- Primary completion1 Oct 2027 (estimated)
- Study completion1 Oct 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Benzodiazepine UseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- MSPU de Pins-Justaret
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07379073
- Sponsor's protocol ID
- Psycho-MG
- Acronym
- Psycho-MG
- Status last verified
- Jan 2026
- First submitted
- 23 Jan 2026
- Last updated
- 30 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of a Clinical Support Website for the Management of Common Mental Health Conditions in Primary Care on Compliance With Benzodiazepine Prescribing Recommendations
- ClinicalTrials.gov ID
- NCT07379073
- Acronym / sponsor ID
- Psycho-MG / Psycho-MG
- Conditions
- Benzodiazepine Use
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- MSPU de Pins-JustaretUniversity, hospital or other
- Study start
- 1 Jun 2026 (estimated)
- Primary completion
- 1 Oct 2027 (estimated)
- Study completion
- 1 Oct 2028 (estimated)
- First posted
- 30 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This cluster-randomized study aims to evaluate the impact of a web-based clinical support tool on adherence to recommended maximum durations for benzodiazepine prescriptions among new users in primary care. General practitioners (GPs) participating in the study will have access to the website, which provides evidence-based algorithms for the management of common mental health conditions, including anxiety and sleep disorders. Prescription data and patient characteristics will be extracted from the French national health insurance database (DCIR). The primary outcome is the proportion of new benzodiazepine users whose prescriptions comply with recommended duration guidelines. Multilevel logistic regression models will assess the intervention effect, adjusting for patient- and GP-level factors.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Experimental Group (trained on PsychoMG website) | Experimental | Other: TrainingTraining intervention on benzodiazepine prescribing with access to the PsychoMG website providing evidence-based clinical decision algorithms for anxiety and sleep disorder management. |
| Control Group | No intervention | –Training intervention on benzodiazepine prescribing without access to the PsychoMG website providing evidence-based clinical decision algorithms for anxiety and sleep disorder management. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (6 listed)
- Being a general practitioner or a specialist in general medicine.
- Practicing in the Occitanie region.
- Working in private practice.
- Being registered under Sector 1 fee agreements.
- Providing informed consent to participate in the study.
Key exclusion criteria (1 listed)
- Physicians who have been practicing for less than two years, as they are unlikely to have sufficient retrospective data on prescription reimbursements for their patients.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TrainingTraining intervention on benzodiazepine prescribing with access to the PsychoMG website providing evidence-based clinical decision algorithms for anxiety and sleep disorder management. | Other | Experimental Group (trained on PsychoMG website) |
Primary outcome
Compliance with recommended maximum duration of benzodiazepine prescriptions among new users
Time frame: 12 months
Primary outcome measure: adherence to recommended prescription duration (yes/no) for benzodiazepines A patient is considered to have a prescription duration for benzodiazepines that is either adherent or non-adherent if they had no benzodiazepine exposure in the previous year and their duration of exposure during the first treatment episode: 1. is less than 12 weeks for anxiolytic benzodiazepines, 2. is less than 28 days for hypnotic benzodiazepines and related drugs, in accordance with current recommendations.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jan 2026.
Related trials for Benzodiazepine Use
RecruitingObservational study
Informative Exhibition for Deprescribing Benzodiazepines
Benzodiazepine-Related Disorders
Recruiting
Brief Motivational Intervention (BMI) on the Deprescription of Benzodiazepines and Related Substances in Adult Chronic Drug Users
Benzodiazepine Withdrawal
Active, not recruiting
Improving Patient Safety by Supporting Older Adults in Managing Sleep Problems.
Benzodiazepines Deprescribing, Sleep Problems
Active, not recruitingObservational study
Treatment Outcomes Among Patients With Prescription Narcotic Drug Use Disorder
Drug Use Disorders
RecruitingObservational study
Benzodiazepine Impact on Cognitive Function: fNIRs and PET/MRI Study
Benzodiazepine Adverse Reaction, Depression, Anxiety
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing Training in people with Benzodiazepine Use, run by MSPU de Pins-Justaret.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 30 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Compliance with recommended maximum duration of benzodiazepine prescriptions among new users (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jan 2026.